FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

    NEXT STORY
    Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration
    PREV STORY
    First US Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer

    author_avatar
    NASDAQ Market News

    RespireRx Pharmaceuticals Inc. Announces Appointment of Timothy Jones as President and Chief Executive Officer

    author_avatar
    NASDAQ Market News

    Capital Senior Living Names Brandon M. Ribar Chief Operating Officer

    author_avatar
    NASDAQ Market News